FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.
What happened
FDA inspected the Agrate Brianza drug manufacturing facility from March 11 to 15, 2024. The agency found that the firm made OTC sunscreen drug products without adequate identity testing of incoming glycerin for diethylene glycol (DEG) and ethylene glycol (EG), relied on supplier certificates without establishing their reliability, inadequately investigated microbial excursions, and kept incomplete laboratory records. It also found data integrity problems in the quality system.
What FDA found
The firm did not test each incoming component lot for identity and all specifications; for glycerin, it lacked a DEG/EG identity test and relied on supplier certificates without establishing their reliability.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm failed to thoroughly investigate microbial excursions in its manufacturing system and changed batch records without adequate explanation or investigation.
21 CFR 211.192Laboratory records were incomplete, such as missing solvent lot numbers and quantities for a finished-product zinc oxide test, and equipment conditions were not peer-reviewed.
21 CFR 211.194(a)The quality system did not adequately ensure the accuracy and integrity of data supporting drug safety, effectiveness, and quality.
21 CFR parts 210 and 211
What FDA wants
FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with its corrections and preventive actions. The firm must also provide requested risk assessments and testing, including DEG/EG test results from reserve samples within 30 calendar days.
Who should pay attention
- brands that buy OTC sunscreen drugs from this contract manufacturer
- companies using glycerin or other high-risk drug components
- drugmakers relying on supplier certificates of analysis
This is a summary. Read the original letter on fda.gov.